Apixaban or Warfarin and Aspirin or Placebo After Acute Coronary Syndrome or Percutaneous Coronary Intervention in Patients With Atrial Fibrillation and Prior Stroke: A Post Hoc Analysis From the AUGUSTUS Trial.
Sign Up to like & getrecommendations! Published in 2022 at "JAMA cardiology"
DOI: 10.1001/jamacardio.2022.1166
Abstract: Importance Data are limited regarding the risk of cerebrovascular ischemic events and major bleeding in patients with atrial fibrillation (AF) and recent acute coronary syndrome (ACS) and/or percutaneous coronary intervention (PCI). Objective Determine the efficacy… read more here.
Keywords: placebo; stroke tia; aspirin; prior stroke ... See more keywords
Aspirin vs Clopidogrel for Long-term Maintenance After Coronary Stenting in Patients With Diabetes: A Post Hoc Analysis of the HOST-EXAM Trial.
Sign Up to like & getrecommendations! Published in 2023 at "JAMA cardiology"
DOI: 10.1001/jamacardio.2023.0592
Abstract: Importance Selecting the optimal antiplatelet agent in patients who have received percutaneous coronary intervention is especially important in those with diabetes due to the heightened risk of ischemic events in this population. Studies on the… read more here.
Keywords: long term; term maintenance; clopidogrel; trial ... See more keywords
Aspirin for Primary Prevention-Time to Rethink Our Approach.
Sign Up to like & getrecommendations! Published in 2022 at "JAMA network open"
DOI: 10.1001/jamanetworkopen.2022.10144
Abstract: Over the past decades, the medical community has witnessed a significant improvement in cardiovascular disease (CVD) outcomes. Nonetheless, CVD remains a leading cause of morbidity and mortality globally. Prevention strategies must address all aspects of… read more here.
Keywords: prevention; low dose; risk; cvd ... See more keywords
Association of Intracranial Hemorrhage Risk With Non–Vitamin K Antagonist Oral Anticoagulant Use vs Aspirin Use: A Systematic Review and Meta-analysis
Sign Up to like & getrecommendations! Published in 2018 at "JAMA Neurology"
DOI: 10.1001/jamaneurol.2018.2215
Abstract: Importance Non–vitamin K antagonist oral anticoagulants (NOACs) might be an attractive choice for stroke prevention in people without atrial fibrillation who may harbor a potential source of cardiac emboli, but not if certain individual NOACs… read more here.
Keywords: risk; use; intracranial hemorrhage; hemorrhage ... See more keywords
Left Ventricular Dysfunction Among Patients With Embolic Stroke of Undetermined Source and the Effect of Rivaroxaban vs Aspirin: A Subgroup Analysis of the NAVIGATE ESUS Randomized Clinical Trial.
Sign Up to like & getrecommendations! Published in 2021 at "JAMA neurology"
DOI: 10.1001/jamaneurol.2021.3828
Abstract: Importance It is uncertain whether anticoagulation is superior to aspirin at reducing recurrent stroke in patients with recent embolic strokes of undetermined source (ESUS) and left ventricular (LV) dysfunction. Objective To determine whether anticoagulation is… read more here.
Keywords: trial; rivaroxaban; dysfunction; aspirin ... See more keywords
Effect of Low-Dose Aspirin on the Course of Age-Related Macular Degeneration: A Secondary Analysis of the ASPREE Randomized Clinical Trial.
Sign Up to like & getrecommendations! Published in 2024 at "JAMA ophthalmology"
DOI: 10.1001/jamaophthalmol.2024.1584
Abstract: Importance Age-related macular degeneration (AMD) is the leading cause of irreversible vision loss in old age. There is no proven intervention to prevent AMD and, apart from lifestyle, nutritional, and supplement advice, there is no… read more here.
Keywords: age; low dose; aspirin; progression ... See more keywords
Aspirin damages the cell wall of Saccharomyces cerevisiae by inhibiting the expression and activity of dolichol‐phosphate mannose synthase 1
Sign Up to like & getrecommendations! Published in 2022 at "FEBS Letters"
DOI: 10.1002/1873-3468.14283
Abstract: Aspirin is a commonly used anti‐inflammatory, analgesic and antithrombotic drug. It has attracted attention due to its potential antifungal therapeutic effect; however, the molecular mechanism is poorly understood. Here, the effects of aspirin on the… read more here.
Keywords: cell wall; expression; wall saccharomyces; saccharomyces cerevisiae ... See more keywords
Long‐term pharmacodynamic and clinical effects of twice‐ versus once‐daily low‐dose aspirin in essential thrombocythemia: The ARES trial
Sign Up to like & getrecommendations! Published in 2024 at "American Journal of Hematology"
DOI: 10.1002/ajh.27418
Abstract: Patients with essential thrombocythemia (ET) are treated with once‐daily low‐dose aspirin to prevent thrombosis, but their accelerated platelet turnover shortens the antiplatelet effect. The short‐term Aspirin Regimens in EsSential Thrombocythemia trial showed that twice‐daily aspirin… read more here.
Keywords: low dose; aspirin; daily low; twice daily ... See more keywords
Effects of chronic low‐dose aspirin treatment on tumor prevention in three mouse models of intestinal tumorigenesis
Sign Up to like & getrecommendations! Published in 2020 at "Cancer Medicine"
DOI: 10.1002/cam4.2881
Abstract: Although early detection and treatment of colorectal cancer (CRC) have improved, it remains a significant health‐care problem with high morbidity and mortality. Data indicate that long‐term intake of low‐dose aspirin reduces the risk of CRC;… read more here.
Keywords: aspirin; low dose; dose aspirin; aspirin treatment ... See more keywords
Implementing subtype‐specific pre‐clinical models of breast cancer to study pre‐treatment aspirin effects
Sign Up to like & getrecommendations! Published in 2022 at "Cancer Medicine"
DOI: 10.1002/cam4.4756
Abstract: Prior data suggest pre‐diagnostic aspirin use impacts breast tumour biology and patient outcome. Here, we employed faithful surgical resection models of HER2+ and triple‐negative breast cancer (TNBC), to study outcome and response mechanisms across breast… read more here.
Keywords: specific pre; implementing subtype; subtype specific; breast cancer ... See more keywords
Does aspirin detract from the benefits of mineralocorticoid receptor antagonists in patients with heart failure and a reduced left ventricular ejection fraction? Probably!
Sign Up to like & getrecommendations! Published in 2017 at "European Journal of Heart Failure"
DOI: 10.1002/ejhf.697
Abstract: There is a wealth of data to show that mineralocorticoid antagonists (MRAs) reduce morbidity and mortality in patients with heart failure when LVEF is reduced and perhaps also when LVEF is fairly well preserved.1–5 Chin… read more here.
Keywords: heart; evidence; aspirin; heart failure ... See more keywords